ClinicalTrials.gg
CompletedNCT01576718Updated May 8, 2018Results posted

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

A Phase 2 interventional study of Fp MDPI and Placebo MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 300 sites in 19 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-05-08.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
889
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
10th of 146
889 · median 100
Started
2012
with 12 others
Phase 2
25 of 147
none open now
Registered
94th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 10th largest by enrollment of the 146 interventional ones that give a count, is one of 13 that started in 2012, is one of 25 in phase 2, and was the 94th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp Spiromax) when administered twice daily in subjects 12 years of age and older with severe persistent asthma who are uncontrolled on high dose ICS therapy.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Dose ranging
  • Fluticasone Propionate
  • Dry Powder Inhaler (DPI)
  • High Dose ICS
  • Asthma
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written /assent signed and dated by the subject and/or parent /legal guardian before conducting any study related procedure.
  2. Male or female 12 years and older, as of the Screening Visit. Male or female 18 years and older, as of the Screening Visit, in countries where local regulations or the regulatory status of study medication permit enrollment of adults only.
  3. General good health, and free of any concomitant conditions or treatment that could interfere with study conduct, influence the interpretation of study observations/results, or put the subject at increased risk during the study.
  4. Asthma Diagnosis: Asthma as defined by the National Institutes of Health (NIH).
  5. Severity of Disease:

    • A best (FEV1) of 40%-85% of the predicted normal value during the Screening Visit. NHANES III predicted values will be used for subjects aged ≥12 years and adjustments to predicted values will be made for African American subjects. ATS/ERS 2005 criteria for acceptability, reproducibility, and end of test must be met for spirometry
  6. Reversibility of Disease: Demonstrated a ≥12% reversibility of FEV1 within 30 minutes following 2 inhalations of albuterol/salbutamol inhalation aerosol (if required, spacers are permitted for reversibility testing only) at the Screening Visit. If a subject fails to demonstrate an increase in FEV1 ≥12% then the subject is not eligible for the study and will not be allowed to re-screen. Reversibility values of 11.50 - 11.99 will be rounded to 12. Documented historical reversibility of ≥ 12 % within 3 months of the Screening Visit will be accepted.
  7. Current Asthma Therapy: Subjects will be required to be on a short acting β2 agonist and inhaled for a minimum of 8 weeks before the Screening Visit and have been maintained on a stable dose of inhaled corticosteroids for four weeks prior to the Screening Visit at one of the following doses:

    • Fluticasone propionate HFA MDI ≥ 880 mcg/day
    • Fluticasone propionate DPI≥ 1000 mcg/day
    • Beclomethasone dipropionate DPI ≥ 2000 mcg/day
    • Beclomethasone dipropionate HFA (QVAR)≥ 640 mcg/day
    • Beclomethasone dipropionate HFA (Clenil Modulite)≥ 2000 mcg/day
    • Budesonide DPI ≥ 1600 mcg/day
    • Budesonide MDI ≥ 1600 mcg/day
    • Flunisolide ≥ 2000 mcg/day
    • Triamcinolone acetonide ≥ 2000 mcg /day
    • Mometasone furoate DPI ≥ 880 mcg/day
    • Ciclesonide HFA MDI ≥ 640 mcg/day

    Exception 1: Based upon the investigator's judgment that there is no inherent harm in changing the subject's current ICS/LABA therapy and the subject provides consent, subjects on inhaled Fluticasone propionate/salmeterol DPI ≥ 1000 mcg/day, or Fluticasone propionate/salmeterol HFA ≥ 880 mcg/day, or Fluticasone propionate/Formoterol ≥ 1000 mcg/day,or Beclomethasone dipropionate/Formoterol ≥ 400 mcg/day, or Budesonide/formoterol HFA ≥ 640 mcg/day, or Budesonide/formoterol DPI ≥ 800 mcg/day, or Mometasone furoate/formoterol MDI ≥ 800 mcg/day or subjects on a qualifying ICS dose plus a long-acting β2-agonists (LABA) administered via separate inhalers, may be switched to a qualifying dose of fluticasone propionate provided the subjects will not participate in the PK portion of the study.

    Exception 2: Subjects on a qualifying dose of fluticasone propionate who wish to participate in the PK portion of the study and who provide consent may have their fluticasone propionate switched to a different qualifying ICS (non-fluticasone propionate) at a pre-screening visit. The subject will be required to return to the clinic to complete the Screening Visit following a 1-week .

  8. Short-Acting β2-Agonists: All subjects must be able to replace their current short-acting β2-agonists with albuterol/salbutamol inhalation aerosol at the Screening Visit for use as needed for the duration of the study. The use of spacer devices with the metered dose inhaler (MDI) will not be allowed during the study with exception of it's use during reversibility testing at the Screening Visit. Nebulized albuterol/salbutamol will not be allowed at any time during the study. Subjects must be able to withhold all inhaled short-acting β2 sympathomimetic bronchodilators for at least 6 hours prior to all study visits.
  9. If female, is currently not pregnant, breast feeding, or attempting to become pregnant, has a negative serum pregnancy test, and is of

    • Non-, defined as:

      • Before menarche, or
      • 1 year , or
      • Surgically sterile (tubal ligation, bilateral oophorectomy, or hysterectomy), or
      • Congenital sterility, or
      • Diagnosed as infertile and not undergoing treatment to reverse infertility or is of
    • Child-bearing potential, willing to commit to using a consistent and acceptable method of as defined below for the duration of the study:

      • Systemic contraception used for 1 month prior to screening, including birth control pills, transdermal patch (Ortho Evra®), vaginal ring (NuvaRing®), levonorgesterel (Norplant®), or injectable progesterone (Depo-Provera®), or
      • Double barrier methods (condoms, cervical cap, diaphragm, and vaginal contraceptive film with spermicide), or
      • Intrauterine device (IUD) or
      • Monogamous with a vasectomized male partner or is of
    • Child-bearing potential and not sexually active, willing to commit to using a consistent and acceptable method of birth control as defined above for the duration of the study, in the event the subject becomes sexually active
  10. Capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements (visits, record-keeping, etc).

Exclusion criteria

Exclusion Criteria:

  1. History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures.
  2. Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of the Screening Visit. In addition, the subject must be excluded if such infection occurs between the Screening Visit and the Randomization Visit.
  3. Any asthma exacerbation requiring oral within 1 month of the Screening Visit. A subject must not have had any hospitalization for asthma within 2 month prior to the Screening Visit.

    Note: An exacerbation of asthma is defined as any worsening of asthma requiring any treatment other than rescue albuterol/salbutamol HFA MDI and/or the subject's regular inhaled corticosteroid maintenance treatment. This includes requiring the use of systemic corticosteroids and/or emergency room visit or hospitalization, a change in the subject's regular inhaled corticosteroid maintenance treatment, or the addition of other asthma medications.

  4. Presence of glaucoma, cataracts, ocular herpes simplex, or other than basal cell carcinoma.
  5. Historical or current evidence of a disease including, but not limited to: cardiovascular (e.g., congestive heart failure, known aortic aneurysm, clinically significant cardiac arrhythmia or coronary heart disease), hepatic, renal, hematological, neuropsychological, endocrine (e.g., uncontrolled diabetes mellitus, uncontrolled thyroid disorder, Addison's disease, Cushing's syndrome), gastrointestinal (e.g., poorly-controlled peptic ulcer, GERD), or pulmonary (e.g., chronic bronchitis, emphysema, bronchiectasis with the need for treatment, cystic fibrosis, bronchopulmonary dysplasia, ). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which could affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  6. Have any of the following conditions that, in the judgment of the investigator, might cause participation in this study to be detrimental to the subject, including, but not limited to:

    • Current malignancy excluding basal cell carcinoma; History of malignancy is acceptable only if the subject has been in remission for one year prior to the Screening Visit. (Remission is defined as no current evidence of malignancy and no treatment for the malignancy in the 12 months prior to the Screening Visit)
    • Current or untreated tuberculosis; History of tuberculosis is acceptable only if a subject has received an approved prophylactic treatment regimen or an approved active treatment regimen and has had no evidence of active disease for a minimum of 2 years
    • Uncontrolled hypertension (systolic BP ≥160 or diastolic BP >100)
    • Stroke within 3 months prior to the Screening Visit
    • Immunologic compromise
  7. History of a positive test for , or infection.
  8. Untreated oral candidiasis at the Screening Visit. Subjects with clinical visual evidence of oral candidiasis and who agree to receive treatment and comply with appropriate medical monitoring may enter the study
  9. History of any adverse reaction to any intranasal, inhaled or systemic corticosteroid therapy. Known or suspected sensitivity to the constituents of the dry powder inhalers (Spiromax or Diskus) used in the study (i.e., lactose).
  10. History of severe allergy to milk protein.
  11. Use of systemic, oral or depot corticosteroids within 4 weeks prior to the Screening Visit

    • Use of topical corticosteroids (≤1% hydrocortisone cream) for dermatological disease is permitted
    • Use of intranasal corticosteroids or ocular corticosteroids at a stable dose for at least 4 weeks prior to the Screening Visit and throughout the study is permitted
  12. Use of medications within 4 weeks prior to the Screening Visit and during the study.
  13. Immunotherapy for the treatment of allergy at a stable maintenance dose for at least 90 days prior to the Screening Visit and which will remain at a stable dose without escalation throughout the study is permitted.
  14. Use of Cytochrome P450 3A4 () inhibitors (e.g., ritonavir, ketoconazole, itraconazole) within 4 weeks prior to the Screening Visit. Strong and moderate CYP3A4 inhibitors are prohibited and weak CYP3A4 are allowed.
  15. History of alcohol or drug abuse within two years preceding the Screening Visit.
  16. Current smoker or a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). A subject may not have used tobacco products within the past one year (e.g., cigarettes, cigars, chewing tobacco, or pipe tobacco).
  17. Study participation by clinical investigator site employees and/or their immediate relatives.
  18. Study participation by more than one subject from the same household at the same time. However, after the study completion or discontinuation by one subject another subject from the same household may be screened.
  19. Participation in any drug study within the 30 days (starting at the final follow-up visit) preceding the Screening Visit or planned participation in another investigational drug study at any time during this study.
  20. Pregnancy, nursing, or plans to become pregnant or donate gametes (ova or sperm) for in vitro fertilization during the study period or for 30 days following the subject's last study related visit (for eligible subjects only - if applicable). Eligible female subjects unwilling to employ appropriate measures to ensure that pregnancy will not occur during the study will be excluded.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
889 participants (actual)

Study arms

  • Experimental
    Fp MDPI 50 mcg

    Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Fp MDPI 100 mcg

    Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Fp MDPI 200 mcg

    Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Experimental
    Fp MDPI 400 mcg

    Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Fp MDPI · Drug: albuterol/salbutamol

  • Placebo comparator
    Placebo MDPI

    Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Other: Placebo MDPI · Drug: albuterol/salbutamol

  • Active comparator
    Flovent Diskus 250mcg

    Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.

    Drug: Flovent Diskus · Drug: albuterol/salbutamol

Interventions

  • Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening.

    Also known as: fluticasone propionate, Fp SPIROMAX® Inhalation Powder

  • OtherPlacebo MDPI

    Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.

  • Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.

    Also known as: Fluticasone propionate

  • Drugalbuterol/salbutamol

    Drug page: Albuterol

    A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

    Also known as: short-acting β2-adrenergic agonists

06

What researchers measure

Primary outcomes

  1. Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period

    Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug, and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12

Secondary outcomes

  1. Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12

  2. Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12

  3. The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12

    The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma. Worsening asthma was defined as: 1. clinic visit FEV1 below the FEV1 stability limit value calculated on Day 1. 2. any 7-day run-in or treatment window (using information from the patient diary) during which the subject experienced: * 3 or more days in which the highest PEF has fallen below the PEF stability limit calculated on Day 1 * 3 or more days in which ≥12 inhalations/day of albuterol/salbutamol was used * 2 or more days in which the subject experienced a nighttime asthma symptom score of \>2 3. clinical asthma exacerbation, defined as worsening asthma requiring any treatment other than study drug or rescue albuterol/salbutamol including the use of systemic corticosteroids and/or ER visit or hospitalization. Patients who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.

    Time frame: Day 1 to Week 12

  4. Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods

    The change from baseline in the percentage of rescue-free 24-hour periods was analyzed with a marginal (also called population averaged) logistic model, with the response being the proportion of rescue-free 24-hour periods. The model included 2 time points of measurement for each subject: the baseline (the last 7 days before the treatment period) and the treatment period. The model contained covariates for sex, age, and treatment. Rescue-free days were as indicated in patient diaries. Data values are estimated means.

    Time frame: Baseline (Day -6 to Day 1 predose), Treatment (Day 1 to Week 12)

  5. Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)

    Time frame: Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose

  6. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose

  7. Time Of Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose

  8. Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 to Week 12

  9. Patients With Positive Swab Test Results for Oral Candidiasis

    Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many patients had positive swab test results. The total number of patients who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Subjects with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.

    Time frame: Screening (Days -21 to -14), Randomization (Day 1), Weeks 1, 2, 3, 4, 6, 8, 10, 12

  10. 24-Hour Urinary Cortisol Excretion at Baseline, Week 12 and Endpoint

    24-hour urinary cortisol excretion was determined from 24-hour pooled-urine samples; urine was refrigerated until return to the investigational site after each 24-hour collection period. Urine was collected within 7 days of Day 1 and within 7 days of Week 12. Urine cortisol sample collection was not required at endpoint visit for subjects who terminated early from the study.

    Time frame: Baseline (Day 1), Week 12, Endpoint

Other outcomes

  1. Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model which includes data from all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12

  2. Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12

  3. Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)

    Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

    Time frame: Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12

07

Results

Posted Apr 12, 2017

Participant flow

Pre-Assignment Period (Run-In Placebo)
Participant flow — Pre-Assignment Period (Run-In Placebo)
MilestonePlacebo MDPI (Run-In)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Started889000000
Completed640000000
Not completed249000000
Withdrew: Inclusion/exclusion criteria49000000
Withdrew: Withdrawal by subject17000000
Withdrew: Randomization criteria not met166000000
Withdrew: Lost to follow-up2000000
Withdrew: Other15000000
Treatment Period
Participant flow — Treatment Period
MilestonePlacebo MDPI (Run-In)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Started0107107106107106107
Safety population0107107106107106106
Efficacy population (full analysis set)0107106102107105103
Completed0828775805877
Not completed0252031274830
Withdrew: Adverse event0111110
Withdrew: Withdrawal by subject0110242
Withdrew: Physician decision0111100
Withdrew: Protocol violation054106812
Withdrew: Sponsor request0100010
Withdrew: Met stopping criteria0161319163315
Withdrew: Lost to follow-up0000100
Withdrew: Noncompliance to study medication0000011

Outcome measures

PrimaryChange From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period

Trough FEV1 was measured electronically by spirometry at morning (AM) investigational site visits, before administration of the AM dose of study drug, and before albuterol/salbutamol administration. The highest FEV1 value from 3 acceptable and 2 reproducible maneuvers was used. All FEV1 data were submitted to a central reading center for evaluation. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline FEV1 + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · liters
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period
litersFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period0.059 ± 0.02690.101 ± 0.02680.109 ± 0.02780.125 ± 0.02740.053 ± 0.0283—
Statistical analysis
  • Fp MDPI 50 mcg vs Fp MDPI 100 mcg vs Fp MDPI 200 mcg vs Fp MDPI 400 mcg vs Placebo MDPI · Regression, Linear · p = 0.0604 (If the Fp MDPI showed a significantly positive trend, then contrasts for pairwise comparisons of each Fp MDPI dose versus placebo were done in the sequence of highest to lowest Fp MDPI dose.)
  • Fp MDPI 400 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0637 (Significance at the 0.05 level.) · Lsm difference: 0.072 · 95% CI -0.004 to 0.149Fp 400 - Placebo
  • Fp MDPI 200 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.1585 (Significance at the 0.05 level) · Lsm difference: 0.056 · 95% CI -0.022 to 0.133Fp 200 - Placebo
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.2221 (Significance at the 0.05 level) · Lsm difference: 0.048 · 95% CI -0.029 to 0.124Fp 100 - Placebo
  • Fp MDPI 50 mcg vs Placebo MDPI · mixed model for repeated measures · p = =0.8694 (Significance at the 0.05 level) · Lsm difference: 0.006 · 95% CI -0.070 to 0.083Fp 50 - Placebo
SecondaryChange From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (non-missing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
liters/minuteFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period10.48 ± 4.2999.34 ± 4.24510.03 ± 4.4209.61 ± 4.3072.24 ± 4.507—
Statistical analysis
  • Fp MDPI 50 mcg vs Fp MDPI 100 mcg vs Fp MDPI 200 mcg vs Fp MDPI 400 mcg vs Placebo MDPI vs Flovent Diskus 250mcg · Regression, Linear · p = 0.1512 (If the Fp MDPI showed a significantly positive trend, then contrasts for pairwise comparisons of each Fp MDPI dose versus placebo were done in the sequence of highest to lowest Fp MDPI dose.)
  • Fp MDPI 400 mcg vs Placebo MDPI · Regression, Linear · p = 0.2361 (Significance at the 0.05 level) · Lsm difference: 7.36 · 95% CI -4.83 to 19.56
  • Fp MDPI 200 mcg vs Placebo MDPI · Regression, Linear · p = 0.2169 · Lsm difference: 7.78 · 95% CI -4.59 to 20.15Significance at the 0.05 level
  • Fp MDPI 100 mcg vs Placebo MDPI · Regression, Linear · p = 0.2523 (Significance at the 0.05 level) · Lsm difference: 7.09 · 95% CI -5.07 to 19.26
  • Fp MDPI 50 mcg vs Placebo MDPI · Regression, Linear · p = 0.1858 (Significance at the 0.05 level) · Lsm difference: 8.23 · 95% CI -3.98 to 20.45
SecondaryChange From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to placebo are from an MMRM model excluding FLOVENT DISKUS data: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period
liters/minuteFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period3.81 ± 4.1836.41 ± 4.2097.45 ± 4.33510.97 ± 4.2083.42 ± 4.462—
Statistical analysis
  • Fp MDPI 50 mcg vs Fp MDPI 100 mcg vs Fp MDPI 200 mcg vs Fp MDPI 400 mcg vs Placebo MDPI · Regression, Linear · p = 0.2879 (If the Fp MDPI showed a significantly positive trend, then contrasts for pairwise comparisons of each Fp MDPI dose versus placebo were done in the sequence of highest to lowest Fp MDPI dose.)
  • Fp MDPI 400 mcg vs Placebo MDPI · Regression, Linear · p = 0.2166 (Significance at the 0.05 level) · Lsm difference: 7.56 · 95% CI -4.45 to 19.56
  • Fp MDPI 200 mcg vs Placebo MDPI · Regression, Linear · p = 0.5167 (Significance at the 0.05 level) · Lsm difference: 4.03 · 95% CI -8.17 to 16.23
  • Fp MDPI 100 mcg vs Placebo MDPI · Regression, Linear · p = 0.6258 (Significance at the 0.05 level) · Lsm difference: 2.99 · 95% CI -9.06 to 15.05
  • Fp MDPI 50 mcg vs Placebo MDPI · Regression, Linear · p = 0.9487 (Significance at the 0.05 level) · Lsm difference: 0.39 · 95% CI -11.60 to 12.39
SecondaryThe Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12

The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma. Worsening asthma was defined as: 1. clinic visit FEV1 below the FEV1 stability limit value calculated on Day 1. 2. any 7-day run-in or treatment window (using information from the patient diary) during which the subject experienced: * 3 or more days in which the highest PEF has fallen below the PEF stability limit calculated on Day 1 * 3 or more days in which ≥12 inhalations/day of albuterol/salbutamol was used * 2 or more days in which the subject experienced a nighttime asthma symptom score of \>2 3. clinical asthma exacerbation, defined as worsening asthma requiring any treatment other than study drug or rescue albuterol/salbutamol including the use of systemic corticosteroids and/or ER visit or hospitalization. Patients who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.

Time frame:
Day 1 to Week 12
Reported as:
Number · probability
The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 12
probabilityFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
The Kaplan-Meier Estimate Of The Probability Of Remaining In The Study At Week 120.6872 (0.5891 to 0.7665)0.6330 (0.5307 to 0.7188)0.5852 (0.4796 to 0.6766)0.6109 (0.5093 to 0.6977)0.4722 (0.3712 to 0.5665)0.5657 (0.4617 to 0.6571)
Statistical analysis
  • Fp MDPI 400 mcg vs Placebo MDPI · Log Rank · p = 0.0341 (Significance level of 0.05.)
  • Fp MDPI 200 mcg vs Placebo MDPI · Log Rank · p = 0.0340 (Significance level of 0.05.)
  • Fp MDPI 100 mcg vs Placebo MDPI · Log Rank · p = 0.0058 (Significance level of 0.05.)
  • Fp MDPI 50 mcg vs Placebo MDPI · Log Rank · p = 0.0018 (Significance level of 0.05.)
  • Placebo MDPI vs Flovent Diskus 250mcg · Log Rank · p = 0.1006 (Significance level of 0.05.)
SecondaryChange From Baseline In The Percentage Of Rescue-Free 24-Hour Periods

The change from baseline in the percentage of rescue-free 24-hour periods was analyzed with a marginal (also called population averaged) logistic model, with the response being the proportion of rescue-free 24-hour periods. The model included 2 time points of measurement for each subject: the baseline (the last 7 days before the treatment period) and the treatment period. The model contained covariates for sex, age, and treatment. Rescue-free days were as indicated in patient diaries. Data values are estimated means.

Time frame:
Baseline (Day -6 to Day 1 predose), Treatment (Day 1 to Week 12)
Reported as:
Mean · percentage of total 24 hour periods
Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods
percentage of total 24 hour periodsFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In The Percentage Of Rescue-Free 24-Hour Periods22.78 ± 4.01626.41 ± 4.01316.18 ± 3.66228.05 ± 3.95127.15 ± 4.47515.87 ± 3.750
Statistical analysis
  • Fp MDPI 400 mcg vs Placebo MDPI · Regression, Linear · p = 0.88116 (Significance at the 0.05 level) · Mean difference (final values): 0.90 · 95% CI -11.12 to 12.91
  • Fp MDPI 200 mcg vs Placebo MDPI · Regression, Linear · p = 0.05977 (Significance at the 0.05 level) · Mean difference (final values): -10.98 · 95% CI -22.64 to 0.68
  • Fp MDPI 100 mcg vs Placebo MDPI · Regression, Linear · p = 0.90426 (Significance at the 0.05 level) · Mean difference (final values): -0.74 · 95% CI -13.02 to 11.54
  • Fp MDPI 50 mcg vs Placebo MDPI · Regression, Linear · p = 0.47310 (Significance at the 0.05 level) · Mean difference (final values): -4.38 · 95% CI -16.57 to 7.82
SecondaryArea Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)
Time frame:
Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Reported as:
Mean · pg*hr/mL
Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)
pg*hr/mLFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Area Under The Plasma Concentration-Time Curve From Time Zero To The Time Of The Last Measurable Concentration (AUC0-t)117.6 ± 145.79126.8 ± 33.73292.0 ± 162.28462.8 ± 262.45—162.3 ± 74.79
SecondaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Reported as:
Mean · pg/mL
Maximum Observed Plasma Concentration (Cmax)
pg/mLFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Maximum Observed Plasma Concentration (Cmax)19.1 ± 15.5326.5 ± 6.1655.2 ± 29.1283.0 ± 44.32—32.5 ± 13.92
SecondaryTime Of Maximum Observed Plasma Concentration (Tmax)
Time frame:
Day 1 predose (within 10 minutes of treatment administration), and 5, 10, 15, 30, and 45 minutes, 1 hour, 1 hour 15 minutes, 1 hour 30 minutes, and 2, 4, 8, and 12 hours postdose
Reported as:
Mean · hours
Time Of Maximum Observed Plasma Concentration (Tmax)
hoursFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Time Of Maximum Observed Plasma Concentration (Tmax)1.0 ± 0.541.2 ± 1.852.2 ± 3.581.4 ± 2.60—1.8 ± 2.75
SecondaryPatients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 to Week 12
Reported as:
Number · participants
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
participantsFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Any adverse event (AE)312734413327
Severe AE311110
Treatment-related AE416952
Deaths000000
Other serious AEs111010
Withdrawn from treatment due to AEs111110
SecondaryPatients With Positive Swab Test Results for Oral Candidiasis

Oropharyngeal examinations for visual evidence of oral candidiasis were conducted at each visit. Any visual evidence of oral candidiasis during the oropharyngeal exam was evaluated by obtaining and analyzing a swab of the suspect area. This outcomes indicates how many patients had positive swab test results. The total number of patients who had oropharyngeal exams at each timepoint are specified in the timepoint field. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation. Subjects with a culture-positive infection could continue participation in the study on appropriate anti-infective therapy, provided this therapy was not prohibited by the protocol.

Time frame:
Screening (Days -21 to -14), Randomization (Day 1), Weeks 1, 2, 3, 4, 6, 8, 10, 12
Reported as:
Number · participants
Patients With Positive Swab Test Results for Oral Candidiasis
participantsFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Screening000000
Day 1001011
Week 1000011
Week 2001200
Week 3000400
Week 4101100
Week 6000100
Week 8001001
Week 10000100
Week 12000101
Secondary24-Hour Urinary Cortisol Excretion at Baseline, Week 12 and Endpoint

24-hour urinary cortisol excretion was determined from 24-hour pooled-urine samples; urine was refrigerated until return to the investigational site after each 24-hour collection period. Urine was collected within 7 days of Day 1 and within 7 days of Week 12. Urine cortisol sample collection was not required at endpoint visit for subjects who terminated early from the study.

Time frame:
Baseline (Day 1), Week 12, Endpoint
Reported as:
Mean · nmol/day
24-Hour Urinary Cortisol Excretion at Baseline, Week 12 and Endpoint
nmol/dayFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Baseline65.3 ± 42.6963.8 ± 44.7066.6 ± 45.5357.4 ± 34.6874.3 ± 43.5466.2 ± 42.68
Week 1271.8 ± 48.3761.5 ± 45.7366.8 ± 53.9646.2 ± 38.6769.2 ± 49.5658.5 ± 43.75
Endpoint71.0 ± 48.3161.5 ± 45.7365.8 ± 53.3345.0 ± 38.3374.4 ± 54.9758.4 ± 43.49
Other pre-specifiedChange From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model which includes data from all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · liters
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
litersFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In Trough (Morning Predose And Pre-Rescue Bronchodilator) Forced Expiratory Volume In 1 Second (FEV1) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)0.063 ± 0.0270.102 ± 0.02690.113 ± 0.02790.129 ± 0.02740.057 ± 0.02840.110 ± 0.0274
Statistical analysis
  • Fp MDPI 400 mcg vs Flovent Diskus 250mcg · mixed model for repeated measures · p = =0.6161 (0.05 level of significance.) · Lsm difference: 0.019 · 95% CI -0.057 to 0.096
  • Fp MDPI 200 mcg vs Flovent Diskus 250mcg · mixed model for repeated measures · p = 0.9245 (0.05 level of significance.) · Lsm difference: 0.004 · 95% CI -0.973 to 0.080
  • Fp MDPI 100 mcg vs Flovent Diskus 250mcg · mixed model for repeated measures · p = 0.8434 (0.05 level of significance.) · Lsm difference: -0.008 · 95% CI -0.083 to 0.068
  • Fp MDPI 50 mcg vs Flovent Diskus 250mcg · mixed model for repeated measures · p = 0.2241 (0.05 level of significance.) · Lsm difference: -0.047 · 95% CI -0.122 to 0.029
  • Placebo MDPI vs Flovent Diskus 250mcg · mixed model for repeated measures · p = 0.1822 (0.05 level of significance.) · Lsm difference: -0.053 · 95% CI -0.130 to 0.025
Other pre-specifiedChange From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. On mornings for which a treatment visit was scheduled (TV1 through TV9), the PEF was measured and recorded at the investigational site visit. Baseline trough AM PEF was defined as the average of recorded (nonmissing) trough AM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
liters/minuteFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Morning Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)10.85 ± 4.2459.39 ± 4.19310.29 ± 4.36210.40 ± 4.2542.52 ± 4.45315.97 ± 4.283
Statistical analysis
  • Fp MDPI 400 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.3568 (0.05 level of significance.) · Lsm difference: -5.56 · 95% CI -17.42 to 6.29
  • Fp MDPI 200 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.3531 (0.05 level of significance.) · Lsm difference: -5.68 · 95% CI -17.67 to 6.32
  • Fp MDPI 100 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.2724 (0.05 level of significance.) · Lsm difference: -6.58 · 95% CI -18.35 to 5.19
  • Fp MDPI 50 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = =0.3964 (0.05 level of significance.) · Lsm difference: -5.11 · 95% CI -16.95 to 6.72
  • Placebo MDPI vs Flovent Diskus 250mcg · Regression, Linear · p = 0.0296 (0.05 level of significance.) · Lsm difference: -13.45 · 95% CI -25.57 to -1.33
Other pre-specifiedChange From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)

Peak expiratory flow was determined in the AM and in the PM, before administration of study or rescue medications using a handheld electronic peak flow meter. The highest value of triplicate measurements obtained was recorded by the subject's diary device. PM PEF baseline was defined as the average of recorded (nonmissing) PM PEF assessments over the 7 days directly preceding first study drug intake. The p-values for the treatment comparisons to Flovent Diskus are from an MMRM model that included data for all treatments: change from baseline = baseline PEF + sex + age + treatment + visit + treatment\*visit with an unstructured covariance matrix assumed.

Time frame:
Baseline (Days -6 to Day 1 pre-dose), Weeks 1, 2, 3, 4, 6, 8, 10 and 12
Reported as:
Least squares mean · liters/minute
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)
liters/minuteFp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcg
Change From Baseline In Weekly Average Of Daily Trough (Predose And Pre-Rescue Bronchodilator) Evening Peak Expiratory Flow (PEF) Over The 12-Week Treatment Period (Including the Flovent Diskus Treatment Arm)4.22 ± 4.2456.52 ± 4.2757.89 ± 4.39711.72 ± 4.2713.35 ± 4.51812.4 ± 4.309
Statistical analysis
  • Fp MDPI 400 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.9101 (0.05 level of significance.) · Lsm difference: -0.69 · 95% CI -12.59 to 11.22
  • Fp MDPI 200 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.4634 (0.05 level of significance.) · Lsm difference: -4.51 · 95% CI -16.6 to 7.57
  • Fp MDPI 100 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.3333 (0.05 level of significance.) · Lsm difference: -5.88 · 95% CI -17.8 to 6.05
  • Fp MDPI 50 mcg vs Flovent Diskus 250mcg · Regression, Linear · p = 0.1763 (0.05 level of significance.) · Lsm difference: -8.19 · 95% CI -20.06 to 3.69
  • Placebo MDPI vs Flovent Diskus 250mcg · Regression, Linear · p = 0.1469 (0.05 level of significance.) · Slope: -9.05 · 95% CI -21.3 to 3.19

Adverse events

Collected over Day 1 to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flovent Diskus 250 mcg—0/106 (0%)4/106 (3.8%)
Fp MDPI 100 mcg—1/107 (0.9%)4/107 (3.7%)
Fp MDPI 200 mcg—1/106 (0.9%)5/106 (4.7%)
Fp MDPI 400 mcg—0/107 (0%)7/107 (6.5%)
Fp MDPI 50 mcg—1/107 (0.9%)5/107 (4.7%)
Placebo MDPI—1/106 (0.9%)6/106 (5.7%)
Most frequent serious events
Most frequent serious events
EventFlovent Diskus 250 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgFp MDPI 50 mcgPlacebo MDPI
Myocardial infarctionCardiac disorders0/1060/1071/1060/1070/1070/106
AsthmaRespiratory, thoracic and mediastinal disorders0/1060/1070/1060/1070/1071/106
Kidney infectionInfections and infestations0/1061/1070/1060/1070/1070/106
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1060/1070/1060/1071/1070/106
Most frequent other events
Most frequent other events
EventFlovent Diskus 250 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgFp MDPI 50 mcgPlacebo MDPI
HeadacheNervous system disorders4/1064/1075/1067/1075/1076/106

Baseline characteristics

Intent to treat analysis set

Age, Continuous
Age, Continuous(years)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Mean47.9 ± 14.5948.7 ± 12.4847.7 ± 14.1850.9 ± 13.3249.8 ± 12.8749.2 ± 13.2649.0 ± 13.46
Age, Customized
Age, Customized(participants)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Adolescents (12-17 years)2311119
Adults (18-64 years)949990909496563
Adults (65-84 years)1151516111068
Sex: Female, Male
Sex: Female, Male(Participants)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Female635566726558379
Male445240354149261
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
White969493919695565
Black912121381165
Asian1112207
American Indian or Alaskan Native0000011
Pacific Islander1000001
Other0001001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Hispanic or Latino578126947
Not Hispanic or Latino102100989510098593
Weight
Weight(kg)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Mean86.7 ± 23.7386.6 ± 22.9084.4 ± 21.8984.4 ± 20.5686.2 ± 25.1983.3 ± 16.7685.3 ± 21.95
Height
Height(cm)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Mean169.4 ± 13.04168.7 ± 9.14168.4 ± 7.86167.4 ± 9.67168.1 ± 8.57168.0 ± 8.33168.3 ± 9.58
Body Mass Index
Body Mass Index(kg/m^2)Fp MDPI 50 mcgFp MDPI 100 mcgFp MDPI 200 mcgFp MDPI 400 mcgPlacebo MDPIFlovent Diskus 250mcgTotal
Mean31.3 ± 17.8830.4 ± 7.6029.8 ± 8.1230.1 ± 6.8130.5 ± 8.8329.6 ± 6.0330.3 ± 10.02

3 further baseline measures are reported on the registry.

08

Study locations

300 sites
  • Teva Investigational Site 10504
    Birmingham, Alabama, United States
  • Teva Investigational Site 10565
    Homewood, Alabama, United States
  • Teva Investigational Site 11527
    Goodyear, Arizona, United States
  • Teva Investigational Site 10516
    Tucson, Arizona, United States
  • Teva Investigational Site 10573
    Bakersfield, California, United States
  • Teva Investigational Site 11518
    Costa Mesa, California, United States
  • Teva Investigational Site 10590
    Fountain Valley, California, United States
  • Teva Investigational Site 10551
    Granada Hills, California, United States
  • Teva Investigational Site 11520
    Huntington Beach, California, United States
  • Teva Investigational Site 11545
    Huntington Beach, California, United States
  • Teva Investigational Site 10547
    Long Beach, California, United States
  • Teva Investigational Site 11549
    Los Angeles, California, United States
  • Teva Investigational Site 10503
    Mission Viejo, California, United States
  • Teva Investigational Site 10536
    Newport Beach, California, United States
  • Teva Investigational Site 10540
    Orange, California, United States
  • Teva Investigational Site 11551
    Orange, California, United States
  • Teva Investigational Site 10578
    Palmdale, California, United States
  • Teva Investigational Site 10585
    Redwood City, California, United States
  • Teva Investigational Site 11538
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 11522
    Roseville, California, United States
  • Teva Investigational Site 10582
    San Diego, California, United States
  • Teva Investigational Site 11554
    San Diego, California, United States
  • Teva Investigational Site 10563
    San Jose, California, United States
  • Teva Investigational Site 11556
    Santa Monica, California, United States
  • Teva Investigational Site 10506
    Stockton, California, United States
  • Teva Investigational Site 10529
    Walnut Creek, California, United States
  • Teva Investigational Site 10545
    Centennial, Colorado, United States
  • Teva Investigational Site 10572
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 10533
    Denver, Colorado, United States
  • Teva Investigational Site 11531
    Denver, Colorado, United States
  • Teva Investigational Site 11542
    Denver, Colorado, United States
  • Teva Investigational Site 11569
    Wheat Ridge, Colorado, United States
  • Teva Investigational Site 10528
    Waterbury, Connecticut, United States
  • Teva Investigational Site 10556
    Boynton Beach, Florida, United States
  • Teva Investigational Site 11513
    Brandon, Florida, United States
  • Teva Investigational Site 11507
    Clearwater, Florida, United States
  • Teva Investigational Site 11546
    Fort Myers, Florida, United States
  • Teva Investigational Site 11526
    Hialeah, Florida, United States
  • Teva Investigational Site 11525
    Kissimmee, Florida, United States
  • Teva Investigational Site 10537
    Miami, Florida, United States
  • Teva Investigational Site 10553
    Miami, Florida, United States
  • Teva Investigational Site 11508
    Miami, Florida, United States
  • Teva Investigational Site 11514
    Miami, Florida, United States
  • Teva Investigational Site 11516
    Miami, Florida, United States
  • Teva Investigational Site 11530
    Miami, Florida, United States
  • Teva Investigational Site 11570
    Miami, Florida, United States
  • Teva Investigational Site 10571
    Ocala, Florida, United States
  • Teva Investigational Site 11537
    Sarasota, Florida, United States
  • Teva Investigational Site 10593
    South Miami, Florida, United States
  • Teva Investigational Site 11555
    Tallahassee, Florida, United States
  • Teva Investigational Site 10554
    Tamarac, Florida, United States
  • Teva Investigational Site 10539
    Tampa, Florida, United States
  • Teva Investigational Site 10525
    Valrico, Florida, United States
  • Teva Investigational Site 11504
    Albany, Georgia, United States
  • Teva Investigational Site 10511
    Columbus, Georgia, United States
  • Teva Investigational Site 11510
    Columbus, Georgia, United States
  • Teva Investigational Site 11572
    Columbus, Georgia, United States
  • Teva Investigational Site 10568
    Lawrenceville, Georgia, United States
  • Teva Investigational Site 10586
    Lilburn, Georgia, United States
  • Teva Investigational Site 11539
    Savannah, Georgia, United States
  • Teva Investigational Site 10543
    Stockbridge, Georgia, United States
  • Teva Investigational Site 11558
    Indianapolis, Indiana, United States
  • Teva Investigational Site 10527
    South Bend, Indiana, United States
  • Teva Investigational Site 10584
    Iowa City, Iowa, United States
  • Teva Investigational Site 11501
    Overland Park, Kansas, United States
  • Teva Investigational Site 10591
    Lexington, Kentucky, United States
  • Teva Investigational Site 11567
    Louisville, Kentucky, United States
  • Teva Investigational Site 10513
    Metairie, Louisiana, United States
  • Teva Investigational Site 10564
    Bangor, Maine, United States
  • Teva Investigational Site 11548
    Baltimore, Maryland, United States
  • Teva Investigational Site 10510
    Largo, Maryland, United States
  • Teva Investigational Site 10577
    Wheaton, Maryland, United States
  • Teva Investigational Site 10538
    Brockton, Massachusetts, United States
  • Teva Investigational Site 10546
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 11502
    Troy, Michigan, United States
  • Teva Investigational Site 10531
    Plymouth, Minnesota, United States
  • Teva Investigational Site 11562
    Columbia, Missouri, United States
  • Teva Investigational Site 11563
    Columbia, Missouri, United States
  • Teva Investigational Site 10552
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10575
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10589
    Saint Louis, Missouri, United States
  • Teva Investigational Site 11532
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10518
    Bellevue, Nebraska, United States
  • Teva Investigational Site 10550
    Omaha, Nebraska, United States
  • Teva Investigational Site 11529
    Omaha, Nebraska, United States
  • Teva Investigational Site 11571
    Las Vegas, Nevada, United States
  • Teva Investigational Site 10559
    Cherry Hill, New Jersey, United States
  • Teva Investigational Site 11566
    Edison, New Jersey, United States
  • Teva Investigational Site 10501
    Hillsborough, New Jersey, United States
  • Teva Investigational Site 11550
    Ocean City, New Jersey, United States
  • Teva Investigational Site 10588
    West Orange, New Jersey, United States
  • Teva Investigational Site 11503
    Albuquerque, New Mexico, United States
  • Teva Investigational Site 10580
    Bronx, New York, United States
  • Teva Investigational Site 10587
    Brooklyn, New York, United States
  • Teva Investigational Site 10520
    New York, New York, United States
  • Teva Investigational Site 10532
    Newburgh, New York, United States
  • Teva Investigational Site 10567
    North Syracuse, New York, United States
  • Teva Investigational Site 10512
    Rochester, New York, United States
  • Teva Investigational Site 10522
    Canton, Ohio, United States
  • Teva Investigational Site 10507
    Cincinnati, Ohio, United States

Showing the first 100 of 300 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bernstein DI, Gillespie M, Song S, Steinfeld J. Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study. J Asthma. 2017 Aug;54(6):559-569. doi: 10.1080/02770903.2016.1242137. Epub 2016 Oct 24. PubMed 27937064 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jul 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 9 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2012
First posted
Apr 12, 2012
Start
Apr 2012
Primary completionActual
Jul 2013
CompletionActual
Oct 2013
Results delay requested
Mar 19, 2015
Results first posted
Apr 12, 2017
Last update
May 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01576718
Responsible party
Sponsor
First posted
Apr 12, 2012
Start date
Apr 2012
Primary completion
Jul 2013
Completion
Oct 2013
Results posted
Apr 12, 2017
Last update
May 8, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion